The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects
Abstract
In most patients with systemic mastocytosis (SM), including aggressive SM and mast cell leukemia (MCL), neoplastic cells express the oncogenic KIT mutation D816V. KIT D816V is associated with constitutive tyrosine kinase (TK) activity and thus represents an attractive drug target. However, imatinib and most other TK inhibitors fail to block the TK activity of KIT D816V. We show that the novel TK-targeting drugs PKC412 and AMN107 counteract TK activity of D816V KIT and inhibit the growth of Ba/F3 cells with doxycycline-inducible expression of KIT D816V as well as the growth of primary neoplastic mast cells and HMC-1 cells harboring this KIT mutation. PKC412 was a superior agent with median inhibitory concentration (IC50) values of 50 to 250 nM without differences seen between HMC-1 cells exhibiting or lacking KIT D816V. By contrast, AMN107 exhibited more potent effects in KIT D816V- HMC-1 cells. Corresponding results were obtained with Ba/F3 cells exhibiting wild-type or D816V-mutated KIT. The growth-inhibitory effects of PKC412 and AMN107 on HMC-1 cells were associated with induction of apoptosis and down-regulation of CD2 and CD63. PKC412 was found to cooperate with AMN107, imatinib, and cladribine (2CdA) in producing growth inhibition in HMC-1, but synergistic drug interactions were observed only in cells lacking KIT D816V. Together, PKC412 and AMN107 represent promising novel agents for targeted therapy of SM. (Blood. 2006;107: 752-759)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Samorapoompichit, P., Kiener, H. P., Schernthaner, G.-H., Jordan, J.-H., Agis, H., Wimazal, F., Baghestanian, M., Rezaie-Majd, A., Sperr, W. R., Lechner, K., et al. (2001) · Blood · doi:10.1182/blood.v98.8.2580 · Cited by 56
Self-citation
Cited by
Paschka, P., Marcucci, G., Ruppert, A. S., Mrózek, K., Chen, H., Kittles, R. A., Vukosavljevic, T., Perrotti, D., Vardiman, J. W., Carroll, A. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.9500 · Cited by 663
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent, P., Akin, C., & Metcalfe, D. D. (2017) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 592
Self-citationAMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A., & Griffin, J. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603170 · Cited by 484
Self-citationAnaphylaxis—a practice parameter update 2015
Lieberman, P., Nicklas, R. A., Randolph, C., Oppenheimer, J., Bernstein, D., Bernstein, J., Ellis, A., Golden, D. B. K., Greenberger, P., Kemp, S., et al. (2015) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2015.07.019 · Cited by 474
Cooperating gene mutations in acute myeloid leukemia: a review of the literature
Renneville, A., Roumier, C., Biggio, V, Nibourel, O., Boissel, N., Fenaux, P., & Preudhomme, C. (2008) · Leukemia · doi:10.1038/leu.2008.19 · Cited by 351
Metadata
- Authors
- Gleixner, K. V., Mayerhofer, M., Aichberger, K. J., Derdak, S., Sonneck, K., Böhm, A., Gruze, A., Samorapoompichit, P., Manley, P. W., Fabbro, D., Pickl, W. F., Sillaber, C., & Valent, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-01-15
- Volume
- 107
- Issue
- 2
- Pages
- 752-759
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2163876274
- Cited by
- 250
- References
- 2
- FWCI
- 6.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. https://app.cochat.ai/papers/10.1182/blood-2005-07-3022
- The paper
- Gleixner, K. V., Mayerhofer, M., Aichberger, K. J., Derdak, S., Sonneck, K., Böhm, A., Gruze, A., Samorapoompichit, P., Manley, P. W., Fabbro, D., Pickl, W. F., Sillaber, C., & Valent, P. (2006). PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood. https://doi.org/10.1182/blood-2005-07-3022
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.